OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data
Autor(a) principal: | |
---|---|
Data de Publicação: | 2015 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Arquivos de neuro-psiquiatria (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2015001000877 |
Resumo: | Trigeminal neuralgia (TN) patients may develop side effects from centrally acting drugs, have contraindications for neurosurgical procedures, or experience relapse during conventional therapies. OnabotulinumtoxinA (BoNT/A) has been reported to be effective for TN, although this finding has been challenged. An overview of the available evidence based on a narrative/qualitative analysis of the literature is presented. About 90% of patients who receive BoNT/A show an improvement, a higher figure than that reported for the placebo effect of BoNT/A for other headaches. Tolerability of BoNT/A is good, and its few side-effects are transient. The articles reviewed were mainly case reports, case series and open-label trials; however, randomized controlled trials have endorsed the efficacy of BoNT/A for TN. This evidence, together with a better understanding of the analgesic mechanisms of BoNT/A and its proven efficacy in treating other pain syndromes, supports the use of this toxin as a therapeutic option for TN. |
id |
ABNEURO-1_9f5fa3a79c7990a3d7af755f951e4c41 |
---|---|
oai_identifier_str |
oai:scielo:S0004-282X2015001000877 |
network_acronym_str |
ABNEURO-1 |
network_name_str |
Arquivos de neuro-psiquiatria (Online) |
repository_id_str |
|
spelling |
OnabotulinumtoxinA for trigeminal neuralgia: a review of the available datatrigeminal neuralgiabotulinum neurotoxin type Abotulinum-A toxinonabotulinumtoxin Aneuropathic painTrigeminal neuralgia (TN) patients may develop side effects from centrally acting drugs, have contraindications for neurosurgical procedures, or experience relapse during conventional therapies. OnabotulinumtoxinA (BoNT/A) has been reported to be effective for TN, although this finding has been challenged. An overview of the available evidence based on a narrative/qualitative analysis of the literature is presented. About 90% of patients who receive BoNT/A show an improvement, a higher figure than that reported for the placebo effect of BoNT/A for other headaches. Tolerability of BoNT/A is good, and its few side-effects are transient. The articles reviewed were mainly case reports, case series and open-label trials; however, randomized controlled trials have endorsed the efficacy of BoNT/A for TN. This evidence, together with a better understanding of the analgesic mechanisms of BoNT/A and its proven efficacy in treating other pain syndromes, supports the use of this toxin as a therapeutic option for TN.Academia Brasileira de Neurologia - ABNEURO2015-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2015001000877Arquivos de Neuro-Psiquiatria v.73 n.10 2015reponame:Arquivos de neuro-psiquiatria (Online)instname:Academia Brasileira de Neurologiainstacron:ABNEURO10.1590/0004-282X20150109info:eu-repo/semantics/openAccessKowacs,Pedro A.Utiumi,Marco A. T.Nascimento,Fábio A.Piovesan,Elcio J.Teive,Helio A. G.eng2015-10-02T00:00:00Zoai:scielo:S0004-282X2015001000877Revistahttp://www.scielo.br/anphttps://old.scielo.br/oai/scielo-oai.php||revista.arquivos@abneuro.org1678-42270004-282Xopendoar:2015-10-02T00:00Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologiafalse |
dc.title.none.fl_str_mv |
OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data |
title |
OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data |
spellingShingle |
OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data Kowacs,Pedro A. trigeminal neuralgia botulinum neurotoxin type A botulinum-A toxin onabotulinumtoxin A neuropathic pain |
title_short |
OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data |
title_full |
OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data |
title_fullStr |
OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data |
title_full_unstemmed |
OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data |
title_sort |
OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data |
author |
Kowacs,Pedro A. |
author_facet |
Kowacs,Pedro A. Utiumi,Marco A. T. Nascimento,Fábio A. Piovesan,Elcio J. Teive,Helio A. G. |
author_role |
author |
author2 |
Utiumi,Marco A. T. Nascimento,Fábio A. Piovesan,Elcio J. Teive,Helio A. G. |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Kowacs,Pedro A. Utiumi,Marco A. T. Nascimento,Fábio A. Piovesan,Elcio J. Teive,Helio A. G. |
dc.subject.por.fl_str_mv |
trigeminal neuralgia botulinum neurotoxin type A botulinum-A toxin onabotulinumtoxin A neuropathic pain |
topic |
trigeminal neuralgia botulinum neurotoxin type A botulinum-A toxin onabotulinumtoxin A neuropathic pain |
description |
Trigeminal neuralgia (TN) patients may develop side effects from centrally acting drugs, have contraindications for neurosurgical procedures, or experience relapse during conventional therapies. OnabotulinumtoxinA (BoNT/A) has been reported to be effective for TN, although this finding has been challenged. An overview of the available evidence based on a narrative/qualitative analysis of the literature is presented. About 90% of patients who receive BoNT/A show an improvement, a higher figure than that reported for the placebo effect of BoNT/A for other headaches. Tolerability of BoNT/A is good, and its few side-effects are transient. The articles reviewed were mainly case reports, case series and open-label trials; however, randomized controlled trials have endorsed the efficacy of BoNT/A for TN. This evidence, together with a better understanding of the analgesic mechanisms of BoNT/A and its proven efficacy in treating other pain syndromes, supports the use of this toxin as a therapeutic option for TN. |
publishDate |
2015 |
dc.date.none.fl_str_mv |
2015-10-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2015001000877 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2015001000877 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/0004-282X20150109 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Academia Brasileira de Neurologia - ABNEURO |
publisher.none.fl_str_mv |
Academia Brasileira de Neurologia - ABNEURO |
dc.source.none.fl_str_mv |
Arquivos de Neuro-Psiquiatria v.73 n.10 2015 reponame:Arquivos de neuro-psiquiatria (Online) instname:Academia Brasileira de Neurologia instacron:ABNEURO |
instname_str |
Academia Brasileira de Neurologia |
instacron_str |
ABNEURO |
institution |
ABNEURO |
reponame_str |
Arquivos de neuro-psiquiatria (Online) |
collection |
Arquivos de neuro-psiquiatria (Online) |
repository.name.fl_str_mv |
Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologia |
repository.mail.fl_str_mv |
||revista.arquivos@abneuro.org |
_version_ |
1754212779229708288 |